Multiplexed Immune Checkpoint Profiling Predicts Atezolizumab Response in Urothelial Carcinoma
A multiplexed FRET-FLIM analysis of immune checkpoint interactions identified patient profiles predictive of response to atezolizumab in urothelial carcinoma.










